Stonegate Updates Coverage on NCS Multistage Holdings, Inc. (NCSM) 2024 Q4

Rhea-AI Summary

NCS Multistage Holdings (NASDAQ: NCSM) reported strong financial results for Q4 2024, with total revenues increasing 28% year-over-year to $45.0 million. The growth was primarily driven by international revenue expansion in both product sales and services, particularly in Middle East tracer diagnostics projects.

Key highlights include:

• Canada achieved 19.5% year-over-year growth
• U.S. performance was mixed with product sales up 29.1% but services down 9.5%
• Consolidated gross margins improved from 36.6% in Q4 2023 to 43.1% in Q4 2024
• Liquidity position strengthened to $46.0M from $37.0M in Q3 2024
• Adjusted EBITDA reached $8.2 million, representing a $5.7 million year-over-year improvement

Positive

• Revenue growth of 28% Y/Y to $45.0M
• Gross margin expansion from 36.6% to 43.1%
• Liquidity position improved by $9.0M to $46.0M
• Adjusted EBITDA increased by $5.7M to $8.2M
• Strong international market performance, especially in Middle East
• Canadian market growth of 19.5% Y/Y

Negative

• U.S. services revenue declined 9.5%
• Potential impact from increasing tariffs threat

Dallas, Texas--(Newsfile Corp. - March 12, 2025) - NCS Multistage Holdings, Inc. (NASDAQ: NCSM): Stonegate Capital Partners updates their coverage on NCS Multistage Holdings, Inc. (NASDAQ: NCSM). In 4Q24, the Company experienced a 28% year-over-year increase in total revenues, reaching $45.0M. This growth was driven by a significant rise in international revenues across both product sales and services, with strength in the Middle East tracer diagnostics projects. Canada also saw strong Y/Y growth of 19.5%. Results were mixed in the U.S. with product sales increasing 29.1 and services revenues decreasing 9.5%. Going forward we expect that the Company will continue to see modest revenue growth through FY25 despite the threat of increasing tariffs. Consolidated gross margins expanded from 36.6% in 4Q23 to 43.1% in 4Q24.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Total revenues of $45.0 million, a 28% year over-year improvement.
• NCSM reported a liquidity position of $46.0M, an increase from $37.0M (3Q24).
• Adjusted EBITDA of $8.2 million, a $5.7 million year-over-year improvement.

Click image above to view full announcement.

---

About Stonegate

Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking, equity research and capital raising for public and private companies.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244309

FAQ

What was NCS Multistage Holdings (NCSM) revenue growth in Q4 2024?

NCSM reported a 28% year-over-year revenue increase to $45.0 million in Q4 2024.

How did NCSM's gross margins perform in Q4 2024 compared to Q4 2023?

NCSM's consolidated gross margins expanded from 36.6% in Q4 2023 to 43.1% in Q4 2024.

What was NCSM's liquidity position in Q4 2024?

NCSM reported a liquidity position of $46.0M, up from $37.0M in Q3 2024.

How much did NCSM's Adjusted EBITDA improve year-over-year in Q4 2024?

NCSM's Adjusted EBITDA reached $8.2 million, a $5.7 million improvement year-over-year.

How did NCSM perform in different geographical regions during Q4 2024?

NCSM saw strong growth in international markets, particularly in Middle East tracer diagnostics, Canada grew 19.5% Y/Y, while U.S. had mixed results with product sales up 29.1% but services down 9.5%.